These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 11585352)
1. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. Riis BJ; Ise J; von Stein T; Bagger Y; Christiansen C J Bone Miner Res; 2001 Oct; 16(10):1871-8. PubMed ID: 11585352 [TBL] [Abstract][Full Text] [Related]
3. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T; J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731 [TBL] [Abstract][Full Text] [Related]
4. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Schimmer RC; Bauss F Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. Eisman JA; Civitelli R; Adami S; Czerwinski E; Recknor C; Prince R; Reginster JY; Zaidi M; Felsenberg D; Hughes C; Mairon N; Masanauskaite D; Reid DM; Delmas PD; Recker RR J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Adami S; Felsenberg D; Christiansen C; Robinson J; Lorenc RS; Mahoney P; Coutant K; Schimmer RC; Delmas PD Bone; 2004 May; 34(5):881-9. PubMed ID: 15121020 [TBL] [Abstract][Full Text] [Related]
7. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. Miller PD; McClung MR; Macovei L; Stakkestad JA; Luckey M; Bonvoisin B; Reginster JY; Recker RR; Hughes C; Lewiecki EM; Felsenberg D; Delmas PD; Kendler DL; Bolognese MA; Mairon N; Cooper C J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327 [TBL] [Abstract][Full Text] [Related]
8. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. Pyon EY Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461 [TBL] [Abstract][Full Text] [Related]
16. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study. Li M; Xing XP; Zhang ZL; Liu JL; Zhang ZL; Liu DG; Xia WB; Meng XW J Bone Miner Metab; 2010 May; 28(3):299-305. PubMed ID: 19855926 [TBL] [Abstract][Full Text] [Related]
17. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Stakkestad JA; Benevolenskaya LI; Stepan JJ; Skag A; Nordby A; Oefjord E; Burdeska A; Jonkanski I; Mahoney P; Ann Rheum Dis; 2003 Oct; 62(10):969-75. PubMed ID: 12972476 [TBL] [Abstract][Full Text] [Related]
18. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Thiébaud D; Burckhardt P; Kriegbaum H; Huss H; Mulder H; Juttmann JR; Schöter KH Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122 [TBL] [Abstract][Full Text] [Related]
19. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Reginster JY Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506 [TBL] [Abstract][Full Text] [Related]
20. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. Reginster JY; Wilson KM; Dumont E; Bonvoisin B; Barrett J J Clin Endocrinol Metab; 2005 Sep; 90(9):5018-24. PubMed ID: 15972582 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]